Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study

被引：4

作者：

Yang, Y. ^{[1
]}

Wang, Z. ^{[2
]}

Fang, J. ^{[3
]}

Yu, Q. ^{[4
]}

Han, B. ^{[5
]}

Cang, S. ^{[6
]}

Chen, G. ^{[7
]}

Mei, X. ^{[8
]}

Yang, Z. ^{[9
]}

Stefaniak, V. ^{[10
]}

Lin, Y. ^{[10
]}

Wang, S. ^{[11
]}

Zhang, W. ^{[11
]}

Sun, L. ^{[11
]}

Zhang, Y. ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China

[2] Shandong Canc Hosp, Jinan, Shandong, Peoples R China

[3] Peking Univ Canc Hosp, Beijing, Peoples R China

[4] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China

[5] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Pulm Med Dept, Shanghai, Peoples R China

[6] Zhengzhou Univ, Henan Prov Hosp, Zhengzhou, Peoples R China

[7] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China

[8] Anhui Prov Hosp, Hefei, Peoples R China

[9] Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China

[10] Eli Lilly & Co, Indianapolis, IN 46285 USA

[11] Innovent Biol Inc, Suzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.02.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4MO

引用

页码：S28 / S28

页数：1

共 50 条

[1] Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
Zhang, Li
Wang, Zhehai
Fang, Jian
Yu, Qitao
Han, Baohui
Cang, Shundong
Chen, Gongyan
Mei, Xiaodong
Yang, Zhixiong
Stefaniak, Victoria
Lin, Yong
Wang, Shuyan
Zhang, Wen
Sun, Luyao
Yang, Yunpeng
LUNG CANCER, 2022, 171 : 56 - 60
[2] Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study
Yang, Yunpeng
Sun, Jiya
Wang, Zhehai
Fang, Jian
Yu, Qitao
Han, Baohui
Cang, Shundong
Chen, Gongyan
Mei, Xiaodong
Yang, Zhixiong
Ma, Rui
Bi, Minghong
Ren, Xiubao
Zhou, Jianying
Li, Baolan
Song, Yong
Feng, Jifeng
Li, Juan
He, Zhiyong
Zhou, Rui
Li, Weimin
Lu, You
Zhou, Hui
Wang, Shuyan
Sun, Luyao
Puig, Oscar
Mancao, Christoph
Peng, Bo
Fang, Wenfeng
Xu, Wei
Zhang, Li
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2109 - 2120
[3] Outcomes of sintilimab plus pemetrexed and platinum (SPP) according to stage of disease in patients (pts) with locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase 3 ORIENT-11 study.
Yang, Yunpeng
Wang, Zhehai
Fang, Jian
Yu, Qitao
Han, Baohui
Cang, Shundong
Chen, Gongyan
Mei, Xiaodong
Yang, Zhixiong
Stefaniak, Victoria Jennifer
Ferry, David Raymond
Zhao, Yumin
Wang, Shuyan
Wang, Yan
Sun, Luyao
Zhang, Li
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] ORIENT-11: Sintilimab plus Pemetrexed plus Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC
Zhang, L.
Yang, Y.
Wang, Z.
Fang, J.
Yu, Q.
Han, B.
Cang, S.
Chen, G.
Mei, X.
Yang, Z.
Ma, R.
Bi, M.
Ren, X.
Zhou, J.
Li, B.
Xu, W.
Ji, Y.
Peng, B.
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) : E41 - E41
[5] Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11)
Yang, Yunpeng
Zhou, Hui
Zhang, Li
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (12) : E191 - E192
[6] Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11)
Fang, J.
Zhao, Y.
Han, B.
Chen, G.
Yang, Z.
Bi, M.
Zhang, L.
Molife, C.
Zhao, Y.
Zhang, L.
ANNALS OF ONCOLOGY, 2021, 32 : S1415 - S1415
[7] Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Yang, Yunpeng
Wang, Zhehai
Fang, Jian
Yu, Qitao
Han, Baohui
Cang, Shundong
Chen, Gongyan
Mei, Xiaodong
Yang, Zhixiong
Ma, Rui
Bi, Minghong
Ren, Xiubao
Zhou, Jianying
Li, Baolan
Song, Yong
Feng, Jifeng
Li, Juan
He, Zhiyong
Zhou, Rui
Li, Weimin
Lu, You
Wang, Yingyi
Wang, Lijun
Yang, Nong
Zhang, Yan
Yu, Zhuang
Zhao, Yanqiu
Xie, Conghua
Cheng, Ying
Zhou, Hui
Wang, Shuyan
Zhu, Donglei
Zhang, Wen
Zhang, Li
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) : 1636 - 1646
[8] ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)
Zhou, C.
Wu, L.
Fan, Y.
Wang, Z.
Liu, L.
Chen, G.
Zhang, L.
Huang, D.
Cang, S.
Yang, Z.
Zhou, J.
Zhou, C.
Li, B.
Li, J.
Fan, M.
Zhang, W.
Yang, W.
Wang, S.
Zhou, H.
ANNALS OF ONCOLOGY, 2020, 31 : S1186 - S1186
[9] A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC
Von Pawel, J.
Papai-Szekely, Z.
Vinolas, N.
Sederholm, C.
Klima, M.
Desaiah, D.
Leschinger, M. I.
Dittrich, C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[10] A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
Yang, James Chih-Hsin
Cheng, Ying
Murakami, Haruyasu
Yang, Pan-Chyr
He, Jianxing
Nakagawa, Kazuhiko
Kang, Jin Hyoung
Kim, Joo-Hang
Hozak, Rebecca R.
Tuan Stevon Nguyen
Zhang, Wan Li
Enatsu, Sotaro
Puri, Tarun
Orlando, Mauro
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) : 91 - 100

← 1 2 3 4 5 →